Table 4.
Descriptive data of the sample of patients with COVID-19 separated by groups of treatment.
| Characteristic | Control (n = 12) | Pentoxifylline (n = 26) | p-value | |
|---|---|---|---|---|
| % change in lymphocytes (basal vs. 48–72 h) | 0.5 (–22.1, 36.7) | 60.3 (28.6, 112.5) | 0.013 | |
| % change in LDH (basal vs. 48–72 h) | −7.9 ± 23.6 | −36.9 ± 20.1 | <0.001 | |
| Days of hospitalization | 13.1 ± 5.6 | 11.2 ± 5.5 | 0.325 | |
| Oxygen saturation | 82.3 ± 8.6 | 86.5 ± 10.3 | 0.227 | |
| paO2a | 49.0 (47.0, 54.0) | 55.0 (49.0, 64.7) | 0.123 | |
| paCO2a | 35.0 (29.0, 42.2) | 30.9 (25.3, 35.0) | 0.238 | |
| Number of concomitant medications n(%) | 2 | 2 (16.7) | 4 (15.4) | 0.348 |
| 3 | 4 (33.3) | 11 (42.3) | ||
| 4 | 6 (50.0) | 7 (26.9) | ||
| 5 | 0 (0.0) | 4 (15.4) | ||
| Mortality n(%) | No | 8 (66.7) | 23 (88.5) | 0.107 |
| Yes | 4 (33.3) | 3 (11.5) | ||
| Need for intubation n(%) | No | 9 (75.0) | 23 (88.5) | 0.290 |
| Yes | 3 (25.0) | 3 (11.5) | ||
a
For these variables, there were data for 15 patients treated with pentoxifylline and nine from the control group.